177Lu-DOTATATE肽受体放射性核素治疗后的持续性血液学功能障碍:胃肠胰神经内分泌肿瘤患者的发生率、病程及预测因素
该研究分析274例胃肠胰神经内分泌肿瘤患者接受177Lu-DOTATATE肽受体放射性核素治疗后的持续性血液学功能障碍,发生率为4%,中位潜伏期41个月,造血系统肿瘤相对危险度2.7(95%CI 0.7-10.0),未发现预测因素。
要点
- 274例胃肠胰神经内分泌肿瘤患者中11例(4%)出现持续性血液学功能障碍。
- 持续性血液学功能障碍中位诊断或首次怀疑时间为41个月(范围15-84个月)。
- 造血系统肿瘤相对危险度为2.7(95%CI 0.7-10.0),未发现持续性血液学功能障碍的危险因素。
核心结论
- 在接受177Lu-DOTATATE肽受体放射性核素治疗的患者人群中,持续性血液学功能障碍的患病率为4%。
- 持续性血液学功能障碍发生的中位时间为首个肽受体放射性核素治疗周期后41个月。
- 发生造血系统肿瘤的相对危险度为2.7,未发现胃肠胰神经内分泌肿瘤患者持续性血液学功能障碍的危险因素。
研究设计与样本
- 研究分析了367例生长抑素受体阳性肿瘤患者中的274例胃肠胰神经内分泌肿瘤患者。
- 持续性血液学功能障碍定义为诊断骨髓增生异常综合征、急性髓系白血病、骨髓增殖性肿瘤、骨髓增生异常/骨髓增殖性肿瘤或其他原因不明的血细胞减少(持续超过6个月)。
- 利用荷兰癌症登记处数据计算预期造血系统肿瘤数,并按性别、年龄和随访期调整。
- 评估的危险因素包括性别、年龄超过70岁、骨转移、既往化疗、既往外照射放疗、[111In-DTPA0]奥曲肽扫描摄取、肿瘤负荷、治疗期间3-4级血液学毒性、估计骨髓吸收剂量、血浆嗜铬粒蛋白A水平升高、基线血细胞计数和肾功能。
主要发现
- 274例患者中11例(4%)在177Lu-DOTATATE治疗后出现持续性血液学功能障碍。
- 8例患者(2.9%)发生造血系统肿瘤:4例骨髓增生异常综合征、1例急性髓系白血病、1例骨髓增殖性肿瘤、2例骨髓增生异常/骨髓增殖性肿瘤。
- 3例患者(1.1%)发生以血细胞减少和骨髓再生障碍为特征的骨髓衰竭。
- 持续性血液学功能障碍诊断或首次怀疑的中位潜伏期为41个月(范围15-84个月)。
- 基于荷兰癌症登记处数据的预期造血系统肿瘤数为3.0,相对危险度为2.7(95%置信区间0.7-10.0)。
关键数值与推荐
- 持续性血液学功能障碍定义为骨髓增生异常综合征、急性髓系白血病、骨髓增殖性肿瘤、骨髓增生异常/骨髓增殖性肿瘤或其他原因不明的血细胞减少持续超过6个月。
- 274例患者中11例(4%)出现持续性血液学功能障碍,其中8例(2.9%)为造血系统肿瘤,3例(1.1%)为骨髓衰竭。
- 持续性血液学功能障碍中位潜伏期为41个月(范围15-84个月)。
- 造血系统肿瘤相对危险度为2.7(95%置信区间0.7-10.0)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peptide receptor radionuclide therapy (PRRT) may induce long-term toxicity to the bone marrow (BM). The aim of this study was to analyze persistent hematologic dysfunction (PHD) after PRRT with 177Lu-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumors (GEP NETs). Methods: The incidence and course of PHD were analyzed in 274 GEP NET patients from a group of 367 patients with somatostatin receptor-positive tumors. PHD was defined as diagnosis of myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), myeloproliferative neoplasm (MPN), MDS/MPN, or otherwise unexplained cytopenia (for >6 mo). Using data from The Netherlands Cancer Registry, the expected number of hematopoietic neoplasms (MDS, AML, MPN, and MDS/MPN) was calculated and adjusted for sex, age, and follow-up period. The following risk factors were assessed: sex, age over 70 y, bone metastasis, prior chemotherapy, prior external-beam radiotherapy, uptake on the [111In-DTPA0]octreotide scan, tumor load, grade 3-4 hematologic toxicity during treatment, estimated absorbed BM dose, elevated plasma chromogranin A level, baseline blood counts, and renal function. Results: Eleven (4%) of the 274 patients had PHD after treatment with 177Lu-DOTATATE: 8 patients (2.9%) developed a hematopoietic neoplasm (4 MDS, 1 AML, 1 MPN, and 2 MDS/MPN) and 3 patients (1.1%) developed BM failure characterized by cytopenia and BM aplasia. The median latency period at diagnosis (or first suspicion of a PHD) was 41 mo (range, 15-84 mo). The expected number of hematopoietic neoplasms based on The Netherlands Cancer Registry data was 3.0, resulting in a relative risk of 2.7 (95% confidence interval, 0.7-10.0). No risk factors for PHD could be identified for the GEP NET patients, not even bone metastasis or estimated BM dose. Seven patients with PHD developed anemia in combination with a rise in mean corpuscular volume. Conclusion: The prevalence of PHD after PRRT with 177Lu-DOTATATE was 4% in our patient population. The median time at which PHD developed was 41 mo after the first PRRT cycle. The relative risk for developing a hematopoietic neoplasm was 2.7. No risk factors were found for the development of PHD in GEP NET patients.
引用
- Bergsma H, van Lom K, Raaijmakers MHGP, et al. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 2017. PMID: 28775205. doi:10.2967/jnumed.117.189712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。